Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Immunology

• Publication date

  2009-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2567.2009.03105.xPMID 19689743PMCID PMC2747147
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition1

  2009cited by this paper
• Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells

  2008cited by this paper
• MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma1

  2008cited by this paper
• Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

  2008cited by this paper
• Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

  2008cited by this paper
• Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

  2007cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• Immune surveillance of tumors.

  2007cited by this paper
• Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

  2006cited by this paper
• Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

  2006cited by this paper
• Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

  2006cited by this paper
• Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.

  2006cited by this paper
• Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1

  2005cited by this paper
• Immunotherapy for pancreatic cancer — science driving clinical progress

  2005cited by this paper
• Animal models of tumor immunity, immunotherapy and cancer vaccines.

  2004cited by this paper
• A Spontaneously Arising Pancreatic Tumor Does Not Promote the Differentiation of Naive CD8+ T Lymphocytes into Effector CTL1

  2004cited by this paper
• Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity.

  2003cited by this paper
• Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis.

  2002cited by this paper
• Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis ☆ ☆☆

  2002cited by this paper
• A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease.

  2001cited by this paper
• Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice.

  1998cited by this paper

• Irreversible electroporation with intratumoral plant virus immunotherapy induces systemic immunity in a metastatic model of pancreatic cancer.

  2025cites this paper
• Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies.

  2025cites this paper
• Aryl Hydrocarbon Receptor Knockout Accelerates PanIN Formation and Fibro-Inflammation in a Mutant Kras-Driven Pancreatic Cancer Model

  2024cites this paper
• Interactions between MDSCs and the Autonomic Nervous System: Opportunities and Challenges in Cancer Neuroscience.

  2024cites this paper
• Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives.

  2024cites this paper
• Genetics and biology of pancreatic ductal adenocarcinoma

  2024cites this paper
• Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma

  2024cites this paper
• Aryl hydrocarbon receptor knockout accelerates PanIN formation and fibro-inflammation in a mutant Kras-driven pancreatic cancer model

  2023cites this paper
• Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment

  2023cites this paper
• Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer

  2023cites this paper
• Reactivation of Anticancer Immunity by Resetting Interorgan Crosstalk in Immune-Suppressive Cells with a Nanoparticulated Anti-Inflammatory Drug.

  2023cites this paper
• Locoregional Therapies and Remodeling of Tumor Microenvironment in Pancreatic Cancer

  2023cites this paper
• Differentiation and Immunological Function of MDSC-Derived Dendritic Cells

  2022cites this paper
• Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice

  2022cites this paper
• The Hepatic Pre-Metastatic Niche

  2022cites this paper
• Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance

  2022cites this paper
• Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia

  2021cites this paper
• Title: Targeting Treg-expressed STAT3 enhances NK-mediated surveillance of metastasis and improves therapeutic response in pancreatic adenocarcinoma and dependent surveillance of in

  2021cites this paper
• Targeting myeloid-derived suppressor cells for cancer therapy

  2021cites this paper
• Phenylboronic acid modified nanoparticles simultaneously target pancreatic cancer and its metastasis and alleviate immunosuppression.

  2021cites this paper
• New Pharmacological Approaches for Pancreatic Cancer Therapy

  2021cites this paper
• MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer

  2021cites this paper
• Myeloid‐derived suppressor cells: Bridging the gap between inflammation and pancreatic adenocarcinoma

  2021cites this paper
• Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.

  2021cites this paper
• PPAR-γ Modulators as Current and Potential Cancer Treatments

  2021cites this paper
• The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions

  2021cites this paper
• Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches

  2021cites this paper
• IL‐6 is associated with expansion of myeloid‐derived suppressor cells and enhanced immunosuppression in pancreatic adenocarcinoma patients

  2021cites this paper
• Anatomical Distribution of Myeloid-Derived Suppressor Cells During HIV Infection

  2021cites this paper
• Targeting Treg-expressed STAT3 enhances NK-mediated surveillance of metastasis and improves therapeutic response in pancreatic adenocarcinoma.

  2021cites this paper
• Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy.

  2020cites this paper
• Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy

  2020cites this paper
• Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment

  2020cites this paper
• Myeloid derived suppressor cells in cancer, premalignancy and inflammation: A roadmap to cancer immunoprevention

  2020cites this paper
• The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities

  2020cites this paper
• Myeloid Cell-Derived Arginase in Cancer Immune Response

  2020cites this paper
• Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

  2020cites this paper
• Mechanisms of T-Cell Exhaustion in Pancreatic Cancer

  2020cites this paper
• Recent advances in myeloid-derived suppressor cell biology

  2020cites this paper
• Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine

  2020cites this paper
• Distribution of Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis and Sjögren’s Syndrome

  2019cites this paper
• Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma.

  2019cites this paper
• Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches

  2019cites this paper
• Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination

  2019cites this paper
• Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model.

  2019cites this paper
• Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune “Defects” in the Tumor Microenvironment

  2019cites this paper
• [Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20].

  2018cites this paper
• Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy

  2018cites this paper
• Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability

  2018cites this paper
• THE IMPACT OF HISTAMINE RECEPTOR 2 ANTAGONISTS ON BREAST CANCER DEVELOPMENT AND MONOCYTIC POPULATIONS

  2018cites this paper
• Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

  2018cites this paper
• The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma

  2018cites this paper
• Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells

  2018cites this paper
• New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers.

  2018cites this paper
• DKK1’S POTENTIAL ROLE AS A BIOMARKER IN PANCREATIC ADENOCARCINOMA By ESEOSASEREA GRACE IGBINIGIE

  2018cites this paper
• Chemotherapy and tumor microenvironment of pancreatic cancer

  2017cites this paper
• MIF-Dependent Regulation of Monocyte/Macrophage Polarization

  2017cites this paper
• Pancreatic Cancer, Pancreatitis, and Oxidative Stress

  2017cites this paper
• Targeting the glucose metabolism of myeloid-derived suppressor cells (MDSCs) to stimulate cancer immunity.

  2017cites this paper
• Myeloid‐derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy

  2017cites this paper
• Suppression of T cells by myeloid-derived suppressor cells in cancer.

  2017cites this paper
• Type of article : Review ( by invitation ) Title : Immune Evasion in Pancreatic Cancer : from Mechanisms to Therapy

  2017cites this paper
• Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients

  2017cites this paper
• Tackling pancreatic cancer with metronomic chemotherapy.

  2017cites this paper
• Macrophage NOS2 in Tumor Leukocytes

  2017cites this paper
• Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques

  2017cites this paper
• PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer

  2017cites this paper
• Immunotherapy in pancreatic cancer treatment: a new frontier

  2017cites this paper
• The Janus-Faced Role of Cell-Mediated Immune Responses in Pancreatic Cancer

  2017cites this paper
• Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages

  2016cites this paper
• From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

  2016cites this paper
• Insights into significant pathways and gene interaction networks in peripheral blood mononuclear cells for early diagnosis of hepatocellular carcinoma.

  2016cites this paper
• Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer

  2016cites this paper
• Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma

  2016cites this paper
• Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b(+)Gr-1(+) cells and its contribution to immunosuppressive activity.

  2016cites this paper
• The Role of nAChR and Calcium Signaling in Pancreatic Cancer Initiation and Progression

  2015cites this paper
• Implication de DOK2 dans la prolifération et la génération de cellules myéloïdes suppressives au cours de la leucémie myélomonocytaire chronique (LMMC)

  2015cites this paper
• Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells

  2015cites this paper
• Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction.

  2015cites this paper
• Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease

  2015cites this paper
• Tumor‐induced CD11b+ Gr‐1+ myeloid‐derived suppressor cells exacerbate immune‐mediated hepatitis in mice in a CD40‐dependent manner

  2015cites this paper
• Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies

  2014cites this paper
• Gr-1 Ab Administered after Bone Marrow Transplantation plus Thymus Transplantation Suppresses Tumor Growth by Depleting Granulocytic Myeloid-Derived Suppressor Cells

  2014cites this paper
• AWARD NUMBER: W81XWH-12-1-0348 TITLE: Activation of Myeloid-Derived Suppressor Cells in Bone Marrow

  2014cites this paper
• Melatonin influences pancreatic cancerogenesis.

  2014cites this paper
• Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages

  2014cites this paper
• Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients

  2014cites this paper
• Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy

  2014cites this paper
• Complex role for the immune system in initiation and progression of pancreatic cancer.

  2014cites this paper
• Myeloid-Derived Suppressor Cells: Paradoxical Roles in Infection and Immunity

  2014cites this paper
• Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.

  2014cites this paper
• Stromal-dependent tumor promotion by MIF family members.

  2014cites this paper
• Association of serum arginase I with L-arginine, 3-nitrotyrosine, and exhaled nitric oxide in healthy Japanese workers

  2014cites this paper
• Pancreatic Cancer Fostered Immunosuppression Privileges Tumor Growth and Progression

  2014cites this paper
• Myeloid derived suppressor cells in patients with Pancreatic Adenocarcinoma

  2014cites this paper
• Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity?

  2014cites this paper
• Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy

  2014cites this paper
• Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival.

  2014cites this paper
• Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.

  2013cites this paper
• Microenvironment and Immunology Parathyroid Hormone – Related Protein Drives a CD 11 b þ Gr 1 þ Cell – Mediated Positive Feedback Loop to Support Prostate Cancer Growth

  2013cites this paper